Cell and Gene Therapy

Segregation in the Design of Gene Therapy Manufacturing Facilities

Peter Walters

CRB USA

Regulatory

No Clinically Meaningful Difference: The Upward Trend of Biosimilars

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch; Carrie Cao, Ph.D.

Nice Insight

Nice Insight Overview

From Digitalization to Nanoscale Delivery: Emerging Technologies Are Driving the Future of Pharma

Nigel Walker

Nice Insight

Clinical Trials

Managing the Complexities of Outbound Clinical Drug Distribution

Ariette van Strien; Wes Wheeler

Marken

API

Right-First-Time Innovation Approach Drives Continual Investment

Adam Kujath

Alcami

Biologics

ADCs: The Future of Biologic Drugs

Guy Tiene; Gabriel Haering, Ph.D.; Thomas Rohrer; Mark Wright, Ph.D.; Scott Miller, Ph.D.; Jean Blehaut

Nice Insight

Innovation

Moving Beyond Monoclonal Antibodies

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch

Nice Insight

Automation

Pharma’s Automation Index on the Rise

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch

Nice Insight

Innovation

Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics

Doug Krafte, Ph.D.; Aaron Gerlach, Ph.D.; Neil Castle, Ph.D.

Icagen

API

Achieving Efficient Pharmaceutical Synthesis with Process Intensification

Stéphane Laurent

Servier

Innovation

Single-Use Operational Excellence Explained: Effective Lifecycle Management

Ariette van Strien; Kenneth Clapp

Marken

Roundtable

Q: Looking forward, what technologies do you anticipate having the greatest impact in 2018?

Pharma's Almanac

Roundtable

Q: What do you see as being the most innovative technologies introduced in 2017? Why were they important? What impacts did they have?

Pharma's Almanac